Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.4K
Overview
33.4K
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

74
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program.

Open forum infectious diseases·2026
Same author

A Gender-Based Descriptive Analysis of the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort From 2015-2023.

Open forum infectious diseases·2026
Same author

Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models.

Science advances·2026
Same author

Corrigendum to "Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study" [Surgery 183 (2025) 109396].

Surgery·2026
Same author

Rapid hepatitis C test and treat with peer support at opioid treatment programs (RAPID HCV): a hybrid effectiveness-implementation type 1 randomized control trial.

Lancet regional health. Americas·2026
Same author

Reply.

Gastroenterology·2026
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Hepatitis B Reactivation: The Controversies Continue.

Jordan J Feld1

  • 1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, ON, Canada.

Digestive Diseases (Basel, Switzerland)
|May 4, 2017
PubMed
Summary
This summary is machine-generated.

Hepatitis B virus (HBV) reactivation during immunosuppressive therapy can be prevented with antiviral prophylaxis. This review clarifies screening, management, and treatment controversies for HBV reactivation, aiming to define best practices.

Keywords:
ChemotherapyHepatitis B reactivationImmunosuppressive therapyRituximab

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Related Experiment Videos

Last Updated: Mar 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Hepatitis B virus (HBV) reactivation is a significant complication of immunosuppressive therapy.
  • Reactivation can lead to severe liver damage, including fulminant liver failure, but is preventable with antiviral prophylaxis.

Purpose of the Study:

  • To review and clarify controversies surrounding HBV reactivation.
  • To discuss screening, management strategies, and antiviral therapy choices for patients at risk.
  • To address emerging issues like reactivation during hepatitis C antiviral therapy.

Main Methods:

  • Literature review of definitions, outcomes, and management strategies for HBV reactivation.
  • Discussion of controversial areas in HBV reactivation screening and treatment.
  • Analysis of current evidence and identification of knowledge gaps.

Main Results:

  • Uncertainty exists regarding optimal screening protocols and indications for antiviral therapy.
  • Definitions of reactivation and management of specific patient groups (e.g., HBsAg negative, anti-HBc positive) vary.
  • HBV reactivation during hepatitis C antiviral therapy is a recognized concern.

Conclusions:

  • Standardized definitions and clear guidelines are needed for HBV reactivation screening and management.
  • Further research is recommended to establish best practices for antiviral prophylaxis and treatment duration.
  • Optimizing management strategies can prevent severe liver complications associated with HBV reactivation.